Ekspresi Protein P53 Sel Trophoblas Plasenta Pada Kehamilan Yang Preeklampsia Berat Eklamsia Dan Kehamilan Normotensi
DAFTAR PUSTAKA
1. Crocker I (2007) Pre-Eclampsia and Villous Trophoblast Turnover:
Perspectives and Possibilities. Placenta.21,pp,4-13.
2. Cunningham FG, McDonal PC, Gant NF, Levano KJ, Gilstrap LC,
Hankins GDV (2010) William Obstetrics, 23rd edition.
3. Heazell AE, Crocker IP (2008) Live and let die - regulation of villous
trophoblast apoptosis in normal and abnormal pregnancies. Placenta
29(9):772–783.
4. Shawn L, Straszewski-Chavez, Vikki M, Abrahams, Gil Mor (2005)
The Role of Apoptosis in the Regulation of Trophoblast Survival and
Differentiation during Pregnancy. Endocrine Reviews 26(7):877–897.
5. Ashe PC, Berry MD (2003) Apoptotic Signaling Cascades. Progress in
Neuro-Psychopharmacology & Biological Psychiatry,27,pp.199-214.
6. Jeschke U et al ( 2006) Expression of the proliferation marker Ki-67
and of p53 tumor protein in trophoblastic tissue of preeclamptic,
HELLP, and intrauterine growth-restricted pregnancies. Int J Gynecol
Pathol 25(4):354–360.58
7. Levy
R
(2005)
The
Role
of
Apoptosis
In
Preeclampsia.
IMAJ,7,pp.178-181.
8. Keman K, Presetyorini N, Langgar MJ (2009) Perbandingan ekspresi
p53,
Bcl-2,
dan
Indeks
Apoptosis
Trofoblas
pada
Preeklampsia/Eklampsia dan Kehamilan Normal. Majalah Obstetri
dan Ginekologi Indonesia,33-3, pp.151-159.
9. Kumar A (2010) Robbins and Cotran Pathologic Basis of Disease. 8th
ed. Saunders,pp.1-11.
10. Leif Matthiesen, Goran Berg, Jan Ernerudh, Christina Ekerfelt,
Yvonne
Jonsson,
Surendra
Sharma
(2005)
Immunology
of
Preeclampsia. Chem Immunol Allergy. Basel, Karger, vol 89, pp 49–
61.
11. Dekker GA, Sibai BM (1998) Etiology and Pathogenesis of
Preeclampsia:Current Consepts. Am J Obstet Gynecol, 179, pp.13591375.
12. Robbert JM, Hubel CA (2009) The Two Stage Model of Preeclampsia:
Variations on the theme. Placenta,23,pp.S32-S37.
13. Hladunewich M, Karumanchi SA, Lafayette R (2007) Pathophysiology
of
Clinical Manifestations of Preeclampsia. Clin J Am Soc
Nephrol,2,pp.543-549.
14. Huppertz (2008) Placental Origins of Preeclampsia: Challenging the
Current Hypothesis. Journal of AHA,5, pp.1970-975.
15. Himpunan Kedokteran Feto Maternal POGI (2005) Pedoman
Pengelolaan Hipertensi Dalam Kehamilan di Indonesia, 2nd ed.
16. Sibai BM (2005) Diagnosis, Prevention, and Management of
Eclampsia. Obstet Gynecol 2005;105:402–10.
17. Gewies A (2003) ApoReview - Introduction to Apoptosis: Page 1 – 26.
18. Levy R et al (2002) Trophoblast apoptosis from pregnancies
complicated by fetal growth restriction is associated with enhanced
p53 expression. Am J Obstet Gynecol 186(5):1056-1061.
19. Levy,R, Smith SD, Chandler K, Sadovsky Y, Nelson M (2000)
Apoptosis in Human Cultured Trophoblast is Enchanced by Hipoksia
and Diminished by Epidermal Growth Factor. Am J Physiol Cell
Physiol,278,pp.982-988.
20. C Hu SD, Smith L, Pang Y, Sadovsky DM, Nelson (2006) Enhanced
Basal Apoptosis in Cultured Term Human Cytotrophoblasts is
Associated with a Higher Expression and Physical Interaction of p53
and Bak. Placenta 27: 978-983.
21. Mauricio Busatto, Lucas Rosa Fraga, Juliano André Boquett, Diego
Luiz Rovaris, Fernanda Sales Luiz Vianna, Lavínia Schuler Faccini,
José Artur Bogo Chies1 and Priscila Vianna,Polymorphisms of the
Apoptotic
genes
TP53
and
MDM2
and
Preeclampsia
Development,Busatto et al., JFIV Reprod Med Genet 2014, 3:1
22. Andrew Neil Sharp, School of Biomedicine, The Role of p53
Modulation in Correcting Abberant Placental Apotosis in Preeclampsia and IUGR, A thesis submitted to the University of
Manchester for the degree of PhD in the Faculty of Medical of Human
Sciences.
23. Drakos, E., V. Atsaves, et al. (2009). "The therapeutic potential of p53
reactivation wild-type or mutated p53."(12): 2290-2299.
24. Drakos, E., A. Thomaides, et al. (2007). "Inhibition of p53-Murine
Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces
Cell Cycle ." 13(11): 3380-3387.
25. de Oca Luna, R. M., D. S. Wagner, et al. (1995). "Rescue of early
embryonic lethality in mdm2-deficient mice by deletion of p53."
378(6553): 203-206.
26. Demir, R., U. A. Kayisli, et al. (2004). "Sequential expression of VEGF
and its receptors in human placental villi during very early pregnancy:
differences between placental vasculogenesis and angiogenesis."
Placenta 25(6): 560-572.
27. Soleymanlou Nima, Jurisica Igor, Nevo Ori, Ietta Francesca, Zhang
Xin, Zamudio Stacy, Post Martin, Caniggia Isabella, Molecular
Evidence of Placental Hypoxia in Preeclampsia, The Journal of
Clinical Endocrinology & Metabolism 90 (7):4299 – 4308.
28. Hladunewich Michelle, Karumanchi S A, Lafayette R, Pathophysiology
of the Clinical Manifestations of Preeclampsia, Cin J Am Soc Nephrol
2 : 543 – 549, 2007. doi: 10.2215/CjN.03761106.
29. Brooks M. Preeclampsia linked to autism, developmental delay.
Medscape Medical News [serial online].December 12, 2014;Accessed
December13,2014.Availableathttp://www.medscape.com/viewarticle/8
36496.
30. Walker CK, Krakowiak P, Baker A, Hansen RL, Ozonoff S,
HertzPicciotto. Preeclampsia, Placental Insufficiency, and Autism
Spectrum Disorder or Developmental Delay. JAMA Pediatr. Dec 8
2014;[Medline].
31. American College of Obstetricians and Gynecologists. Hypertension
in pregnancy. ACOG TechnicalBulletin No. 219. Washington DC:
1996. Taylor RN, de Groot CJ, Cho YK, et al. Circulating factors as
markers
and
mediators
of
endothelial
cell
dysfunction
in
preeclampsia. Semin Reprod Endocrinol. 1998;16(1):1731.[Medline].
32. Barron WM, Heckerling P, Hibbard JU, et al. Reducing unnecessary
coagulation testing in hypertensive disorders of pregnancy. Obstet
Gynecol. Sep 1999;94(3):36470.[Medline].
33. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons
learned
from
recent
trials.
Am
J
ObstetGynecol.
Jun
2004;190(6):15206.[Medline].
34. Sibai BM. Diagnosis and management of gestational hypertension
and preeclampsia. Obstet Gynecol. Jul2003;102(1):18192.[Medline].
35. Ness RB, Roberts JM. Heterogeneous causes constituting the single
syndrome of preeclampsia: ahypothesis and its implications. Am J
Obstet Gynecol. Nov 1996;175(5):136570.[Medline].
36. Vatten LJ, Skjaerven R. Is preeclampsiamore than one disease?.
BJOG. Apr 2004;111(4):298302.[Medline].
37. . Villar J, Betran AP, Gulmezoglu M. Epidemiological basis for the
planning of maternal health services.WHO/RHR. 2001.
38. Khedun SM, Moodley J, Naicker T, et al. Drug management of
hypertensive
disorders
of
pregnancy.Pharmacol
Ther.
1997;74(2):22158.[Medline]
39. 12. Ngoc NT, Merialdi M, AbdelAleemH, Carroli G, Purwar M,
Zavaleta N, et al. Causes of stillbirths andearly neonatal deaths: data
from 7993 pregnancies in six developing countries. Bull World Health
Organ.Sep 2006;84(9):699705.[Medline]. [Full Text].
40. Report of the National High Blood Pressure Education Program
Working Group on High Blood Pressure inPregnancy. Am J Obstet
Gynecol. Jul 2000;183(1):S1S22.Medline].
1. Crocker I (2007) Pre-Eclampsia and Villous Trophoblast Turnover:
Perspectives and Possibilities. Placenta.21,pp,4-13.
2. Cunningham FG, McDonal PC, Gant NF, Levano KJ, Gilstrap LC,
Hankins GDV (2010) William Obstetrics, 23rd edition.
3. Heazell AE, Crocker IP (2008) Live and let die - regulation of villous
trophoblast apoptosis in normal and abnormal pregnancies. Placenta
29(9):772–783.
4. Shawn L, Straszewski-Chavez, Vikki M, Abrahams, Gil Mor (2005)
The Role of Apoptosis in the Regulation of Trophoblast Survival and
Differentiation during Pregnancy. Endocrine Reviews 26(7):877–897.
5. Ashe PC, Berry MD (2003) Apoptotic Signaling Cascades. Progress in
Neuro-Psychopharmacology & Biological Psychiatry,27,pp.199-214.
6. Jeschke U et al ( 2006) Expression of the proliferation marker Ki-67
and of p53 tumor protein in trophoblastic tissue of preeclamptic,
HELLP, and intrauterine growth-restricted pregnancies. Int J Gynecol
Pathol 25(4):354–360.58
7. Levy
R
(2005)
The
Role
of
Apoptosis
In
Preeclampsia.
IMAJ,7,pp.178-181.
8. Keman K, Presetyorini N, Langgar MJ (2009) Perbandingan ekspresi
p53,
Bcl-2,
dan
Indeks
Apoptosis
Trofoblas
pada
Preeklampsia/Eklampsia dan Kehamilan Normal. Majalah Obstetri
dan Ginekologi Indonesia,33-3, pp.151-159.
9. Kumar A (2010) Robbins and Cotran Pathologic Basis of Disease. 8th
ed. Saunders,pp.1-11.
10. Leif Matthiesen, Goran Berg, Jan Ernerudh, Christina Ekerfelt,
Yvonne
Jonsson,
Surendra
Sharma
(2005)
Immunology
of
Preeclampsia. Chem Immunol Allergy. Basel, Karger, vol 89, pp 49–
61.
11. Dekker GA, Sibai BM (1998) Etiology and Pathogenesis of
Preeclampsia:Current Consepts. Am J Obstet Gynecol, 179, pp.13591375.
12. Robbert JM, Hubel CA (2009) The Two Stage Model of Preeclampsia:
Variations on the theme. Placenta,23,pp.S32-S37.
13. Hladunewich M, Karumanchi SA, Lafayette R (2007) Pathophysiology
of
Clinical Manifestations of Preeclampsia. Clin J Am Soc
Nephrol,2,pp.543-549.
14. Huppertz (2008) Placental Origins of Preeclampsia: Challenging the
Current Hypothesis. Journal of AHA,5, pp.1970-975.
15. Himpunan Kedokteran Feto Maternal POGI (2005) Pedoman
Pengelolaan Hipertensi Dalam Kehamilan di Indonesia, 2nd ed.
16. Sibai BM (2005) Diagnosis, Prevention, and Management of
Eclampsia. Obstet Gynecol 2005;105:402–10.
17. Gewies A (2003) ApoReview - Introduction to Apoptosis: Page 1 – 26.
18. Levy R et al (2002) Trophoblast apoptosis from pregnancies
complicated by fetal growth restriction is associated with enhanced
p53 expression. Am J Obstet Gynecol 186(5):1056-1061.
19. Levy,R, Smith SD, Chandler K, Sadovsky Y, Nelson M (2000)
Apoptosis in Human Cultured Trophoblast is Enchanced by Hipoksia
and Diminished by Epidermal Growth Factor. Am J Physiol Cell
Physiol,278,pp.982-988.
20. C Hu SD, Smith L, Pang Y, Sadovsky DM, Nelson (2006) Enhanced
Basal Apoptosis in Cultured Term Human Cytotrophoblasts is
Associated with a Higher Expression and Physical Interaction of p53
and Bak. Placenta 27: 978-983.
21. Mauricio Busatto, Lucas Rosa Fraga, Juliano André Boquett, Diego
Luiz Rovaris, Fernanda Sales Luiz Vianna, Lavínia Schuler Faccini,
José Artur Bogo Chies1 and Priscila Vianna,Polymorphisms of the
Apoptotic
genes
TP53
and
MDM2
and
Preeclampsia
Development,Busatto et al., JFIV Reprod Med Genet 2014, 3:1
22. Andrew Neil Sharp, School of Biomedicine, The Role of p53
Modulation in Correcting Abberant Placental Apotosis in Preeclampsia and IUGR, A thesis submitted to the University of
Manchester for the degree of PhD in the Faculty of Medical of Human
Sciences.
23. Drakos, E., V. Atsaves, et al. (2009). "The therapeutic potential of p53
reactivation wild-type or mutated p53."(12): 2290-2299.
24. Drakos, E., A. Thomaides, et al. (2007). "Inhibition of p53-Murine
Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces
Cell Cycle ." 13(11): 3380-3387.
25. de Oca Luna, R. M., D. S. Wagner, et al. (1995). "Rescue of early
embryonic lethality in mdm2-deficient mice by deletion of p53."
378(6553): 203-206.
26. Demir, R., U. A. Kayisli, et al. (2004). "Sequential expression of VEGF
and its receptors in human placental villi during very early pregnancy:
differences between placental vasculogenesis and angiogenesis."
Placenta 25(6): 560-572.
27. Soleymanlou Nima, Jurisica Igor, Nevo Ori, Ietta Francesca, Zhang
Xin, Zamudio Stacy, Post Martin, Caniggia Isabella, Molecular
Evidence of Placental Hypoxia in Preeclampsia, The Journal of
Clinical Endocrinology & Metabolism 90 (7):4299 – 4308.
28. Hladunewich Michelle, Karumanchi S A, Lafayette R, Pathophysiology
of the Clinical Manifestations of Preeclampsia, Cin J Am Soc Nephrol
2 : 543 – 549, 2007. doi: 10.2215/CjN.03761106.
29. Brooks M. Preeclampsia linked to autism, developmental delay.
Medscape Medical News [serial online].December 12, 2014;Accessed
December13,2014.Availableathttp://www.medscape.com/viewarticle/8
36496.
30. Walker CK, Krakowiak P, Baker A, Hansen RL, Ozonoff S,
HertzPicciotto. Preeclampsia, Placental Insufficiency, and Autism
Spectrum Disorder or Developmental Delay. JAMA Pediatr. Dec 8
2014;[Medline].
31. American College of Obstetricians and Gynecologists. Hypertension
in pregnancy. ACOG TechnicalBulletin No. 219. Washington DC:
1996. Taylor RN, de Groot CJ, Cho YK, et al. Circulating factors as
markers
and
mediators
of
endothelial
cell
dysfunction
in
preeclampsia. Semin Reprod Endocrinol. 1998;16(1):1731.[Medline].
32. Barron WM, Heckerling P, Hibbard JU, et al. Reducing unnecessary
coagulation testing in hypertensive disorders of pregnancy. Obstet
Gynecol. Sep 1999;94(3):36470.[Medline].
33. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons
learned
from
recent
trials.
Am
J
ObstetGynecol.
Jun
2004;190(6):15206.[Medline].
34. Sibai BM. Diagnosis and management of gestational hypertension
and preeclampsia. Obstet Gynecol. Jul2003;102(1):18192.[Medline].
35. Ness RB, Roberts JM. Heterogeneous causes constituting the single
syndrome of preeclampsia: ahypothesis and its implications. Am J
Obstet Gynecol. Nov 1996;175(5):136570.[Medline].
36. Vatten LJ, Skjaerven R. Is preeclampsiamore than one disease?.
BJOG. Apr 2004;111(4):298302.[Medline].
37. . Villar J, Betran AP, Gulmezoglu M. Epidemiological basis for the
planning of maternal health services.WHO/RHR. 2001.
38. Khedun SM, Moodley J, Naicker T, et al. Drug management of
hypertensive
disorders
of
pregnancy.Pharmacol
Ther.
1997;74(2):22158.[Medline]
39. 12. Ngoc NT, Merialdi M, AbdelAleemH, Carroli G, Purwar M,
Zavaleta N, et al. Causes of stillbirths andearly neonatal deaths: data
from 7993 pregnancies in six developing countries. Bull World Health
Organ.Sep 2006;84(9):699705.[Medline]. [Full Text].
40. Report of the National High Blood Pressure Education Program
Working Group on High Blood Pressure inPregnancy. Am J Obstet
Gynecol. Jul 2000;183(1):S1S22.Medline].